BioActor and Nestlé Health Science to collaborate on nutritional products containing Bonolive®
Maastricht, Netherlands/Vevey, Switzerland, 4 may 2015 – Today BioActor announced that it has engaged in a collaboration with Nestlé Health Science on the development of nutritional products containing Bonolive®.
Bonolive® is a health ingredient based on olive polyphenols, targeting bone health. Bonolive® has shown to stimulate osteoblast – bone producing cell – activity in a 12 months clinical study. The results of this study were recently published in the journal of nutrition, health & aging. Bonolive® has further shown in a pharmacokinetics study to have excellent bioavailability and to improve serum antioxidant status in healthy subjects.
“We are excited to work together with Nestlé Health Science,” says Hans van der Saag, managing director and founder of BioActor. “This collaboration first of all aims to strengthen scientific evidence for the benefits of Bonolive®. With our combined capabilities I am confident that we will develop novel applications addressing well defined nutritional requirements, based on the newest scientific insights.”
Financial and other terms of the collaboration are not disclosed.
=== END OF PRESS RELEASE ===
About BioActor and Nestlé Health Science
BioActor, based in Maastricht, Netherlands, is a product development company that supplies proprietary bioactive formulations to the nutrition & healthcare industry. The company focuses on the development of innovative bioactives that address ageing related chronic health conditions. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
For further information, see www.BioActor.com or contact Hans van der Saag, managing director, on +31 4 3711 4555, or mail to: hans.vandersaag@BioActor.com
Nestlé Health Science, a wholly-owned subsidiary of Nestlé, is a health-science company engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and our partners in healthcare. Its portfolio of nutrition solutions, diagnostics, devices and drugs target a number of health areas, such as inborn errors of metabolism, pediatric and acute care, obesity care, healthy ageing, and gastrointestinal and brain health. Through investing in innovation and leveraging leading edge science, we bring forward innovative nutritional therapies with proven clinical, health economic value and quality of life benefits. Nestlé Health Science employs around 3,000 people worldwide and is headquartered in Vevey, Switzerland.
For more information, please visit www.nestlehealthscience.com.